戻る Agenda
Session 5 Track C - Science, Quality, and Good Manufacturing Practices: Good Manufacturing Practices: Compliance Trends and Initiatives
Session Chair(s)
Maggie Graham
Senior Policy Analyst, Natural and Non-Prescription Health Products Directorate
Health Canada, Canada
Over the last several years, the drug manufacturing industry, like many others, has evolved a complex, networked approach to manufacturing. Recent trends and transparency initiatives related to inspections will be discussed from the regulator and industry perspective
Speaker(s)
Compliance and Enforcement Trends and Initiatives
Sara O'Connor
Health Canada, Canada
Director, Office of Business Transformation
Co-Presenter
Daniel McLean
Health Canada, Canada
Senior Policy Advisor
Industry Perspective
Sandra Usik
Eli Lilly Canada Inc, Canada
Associate VP, Reg. Affairs, Quality & Compliance